September 2016
Volume 57, Issue 12
Open Access
ARVO Annual Meeting Abstract  |   September 2016
Treatment of Haplogroup H and K ARPE-19 Cybrids with β-Amyloid
Author Affiliations & Notes
  • Kunal Thaker
    Ophthalmology, Gavin Herbet Eye Institute - UCI, Irvine, California, United States
  • Marilyn Chwa
    Ophthalmology, Gavin Herbet Eye Institute - UCI, Irvine, California, United States
  • Shari R Atilano
    Ophthalmology, Gavin Herbet Eye Institute - UCI, Irvine, California, United States
  • Tej Patel
    Ophthalmology, Gavin Herbet Eye Institute - UCI, Irvine, California, United States
  • Cristina M Kenney
    Ophthalmology, Gavin Herbet Eye Institute - UCI, Irvine, California, United States
  • Footnotes
    Commercial Relationships   Kunal Thaker, None; Marilyn Chwa, None; Shari Atilano, None; Tej Patel, None; Cristina Kenney, None
  • Footnotes
    Support  Discovery Eye Foundation, Guenther Foundation, Beckman Initiative for Macular Research, Polly and Michael Smith Foundation, Max Factor Family Foundation, Iris and B. Gerald Cantor Foundation.
Investigative Ophthalmology & Visual Science September 2016, Vol.57, 256. doi:
  • Views
  • Share
  • Tools
    • Alerts
      ×
      This feature is available to authenticated users only.
      Sign In or Create an Account ×
    • Get Citation

      Kunal Thaker, Marilyn Chwa, Shari R Atilano, Tej Patel, Cristina M Kenney; Treatment of Haplogroup H and K ARPE-19 Cybrids with β-Amyloid. Invest. Ophthalmol. Vis. Sci. 2016;57(12):256.

      Download citation file:


      © ARVO (1962-2015); The Authors (2016-present)

      ×
  • Supplements
Abstract

Purpose : Ashkenazi Jewish populations, mainly of the mitochondrial (mt) haplogroup K, have been observed to have increased rates of hypercholesterolemia, a risk factor for age-related macular degeneration (AMD), compared to other Caucasian populations. Apolipoprotein E (apoE) is a protein involved in lipid transport, and processing the pathogenic peptide amyloid-β (am-β), known to have a role in Alzheimer’s and AMD. Haplogroup H and K adult retinal pigmental epithelial (ARPE) cytoplasmic hybrids (cybrids) were treated with amyloid-β1-42 (am-β1-42) to determine if the differences in APOE expression affected cellular response.

Methods : H (n=6) and K (n=8) haplogroup cybrids were created using platelets from individuals. RNA and DNA were isolated from cells cultured to the fifth passage. GeneChip Array Analysis was performed to find the highest differential gene expression between the two haplogroups and qPCR was performed on genes of interest. Cells were plated on 96-well plates (5x104 cells per well) and treated with 20µM am-β1-42 after 24 hours. An MTT assay was done to observe cell viability 24 hours after treating. Each sample’s data was normalized to its untreated average. Statistical significance was determined through a student’s t-test.

Results : GeneChip Array Analysis found that the K cybrids had increased gene expression in the atherosclerosis pathways compared to H cybrids. QPCR showed that the K cybrids had a 9.3-fold increase in the expression of APOE compared to the haplogroup H cybrids (p<0.0001). APOC1, COL1A1, and MMP1 were also measured but no significant difference was found between the H and K cybrids. After treatment with am-β1-42 the cell viability in H cybrids dropped 30% ± 2.3% (p<0.001), while the K cybrids decreased 16% ± 2.0% (p<0.0001) relative to their respective untreated controls. The difference in viability between the H and K cybrids post treatment was 14.7% (p<0.0001).

Conclusions : These findings demonstrate that cells with haplogroup K mtDNA transcribe higher levels of APOE and are more resistant to am-β1-42 toxicity compared to the cells with haplogroup H mtDNA. In other systems, apoE enhances the elimination of am-β and provides cyto-protection. Our results suggest that in human RPE cells, higher levels of APOE expression may have protective functions against the pathogenic effects of am-β. These findings indicate that mtDNA may mediate levels of APOE expression and play a role in apoE-related diseases.

This is an abstract that was submitted for the 2016 ARVO Annual Meeting, held in Seattle, Wash., May 1-5, 2016.

×
×

This PDF is available to Subscribers Only

Sign in or purchase a subscription to access this content. ×

You must be signed into an individual account to use this feature.

×